ViewRay (VRAY) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year price targets for ViewRay's stock. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $3.18 in the next twelve months.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our VRAY earnings forecast.

ViewRay, Inc. (NASDAQ:VRAY) posted its earnings results on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to the consensus estimate of $34.65 million. ViewRay had a negative net margin of 104.30% and a negative trailing twelve-month return on equity of 120.48%. The firm's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS.

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

ViewRay's stock is owned by many different retail and institutional investors. Top institutional investors include Hodges Capital Management Inc. (1.42%), Parallax Volatility Advisers L.P. (0.00%), Royce & Associates LP (0.53%), Jefferies Financial Group Inc. (0.00%), Simplex Trading LLC (0.00%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Adam Andrew Podbelski, B Kristine Johnson, Brian K Roberts, Caley Castelein, Farhad Fred Ebrahimi, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Karen Prange, Paul Ziegler Jr, Sanket Shah, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends.

ViewRay (NASDAQ:VRAY) has a market capitalization of $0.00 and generates $105.86 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 295 workers across the globe.

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.